尼妥珠单抗
医学
内科学
放化疗
不利影响
放射治疗
临床终点
肿瘤科
粘膜炎
前瞻性队列研究
胃肠病学
临床试验
癌症
表皮生长因子受体
作者
Xin Wang,Ning Yu,Guowei Cheng,Jiao Li,Jun Liang,Tao Zhang,Lei Deng,Wenyang Liu,Jianyang Wang,Yirui Zhai,Wenqing Wang,Zhijian Xiao,Zongmei Zhou,Dongfu Chen,Qinfu Feng,Nan Bi
出处
期刊:Current Cancer Drug Targets
[Bentham Science]
日期:2023-09-01
卷期号:23 (8): 653-662
标识
DOI:10.2174/1568009623666230315145937
摘要
Background: Concurrent or definitive chemoradiotherapy is the standard treatment of locally advanced esophageal squamous cell carcinoma (ESCC). Elderly patients could not tolerate the standard concurrent chemotherapy and were treated with radiotherapy because of weak physical status and multiple comorbidities. Objective: The efficacy and safety profile of concurrent (chemo) radiotherapy combined with nimotuzumab in elderly patients with ESCC were investigated. Methods: Eligible elderly (≥70 years) patients with locally advanced ESCC were enrolled in this prospective, real-world pragmatic study and received concurrent chemoradiotherapy or radiotherapy combined with nimotuzumab. The primary endpoint was overall survival (OS). Secondary endpoints were objective response rate, disease control rate, progression-free survival (PFS), and adverse drug reactions. Results: Fifty-three elderly patients were enrolled. Thirty-two (60.4%) were treated with radiotherapy combined with nimotuzumab (RT+N), and 21 (39.6%) with concurrent chemoradiotherapy combined with nimotuzumab (CRT+N). The median age was 75.8 years. Fourteen (56.0%) patients achieved a partial response, and 11 (44.0%) patients achieved stable disease at 3 months. The median follow-up duration was 24.4 (95%CI, 21.6-26.7) months. Median OS (mOS) was 27.0 (95%CI, 14.8-48.4) months. Median PFS (mPFS) was 22.6 (95%CI, 12.4-not reached) months. Higher mPFS (not reached vs. 12.0 months; p=0.022) and mOS (48.4 vs. 15.3 months; p=0.009) were observed in the CRT+N group compared with the RT+N group. Most adverse reactions were grade 1-2 (46, 86.8%). Conclusions: Concurrent chemoradiotherapy or radiotherapy combined with nimotuzumab was safe and well-tolerated in elderly patients with locally advanced ESCC. ESCC patients treated with CRT+N could live longer.
科研通智能强力驱动
Strongly Powered by AbleSci AI